Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet
Financial Analysis: Prelude Therapeutics (NASDAQ:PRLD) versus Bioasis Technologies (OTCMKTS:BIOAF)
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
Prelude Therapeutics (NASDAQ:PRLD) vs. Aptorum Group (NASDAQ:APM) Critical Review
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
Analyzing BioCryst Pharmaceuticals (NASDAQ:BCRX) and Prelude Therapeutics (NASDAQ:PRLD)
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
Prelude Therapeutics Incorporated (PRLD) Q3 2025 Earnings Call Transcript
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm
Prelude Therapeutics Announces Strategic Business Update
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Prelude Therapeutics (PRLD) Projected to Post Earnings on Wednesday
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Two Sigma Investments LP Purchases 174,906 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD)
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Prelude Therapeutics to Participate in Citizens Life Sciences Conference
Prelude Announces Presentations at 2025 AACR Annual Meeting
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD)
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD)
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024